Detailed narrative
Turnaround thesis: from cost-cutting to investing for growth
Management framed the quarter against the backdrop of four declining revenue/profit years through 2023, now stabilized. Rather than 'save your way to prosperity,' Biogen reworked every P&L line to invest for growth, notably reshifting commercial spend that was ~90% behind the MS portfolio in 2023 toward newer growth products.
Those growth products delivered $851M (+12% YoY) and now out-earn the remaining MS portfolio, evidencing the reallocation is working.
Apellis acquisition — pipeline lands on a growing base
The pending Apellis acquisition adds Syfovre and Empaveli (one molecule, three indications, two brands). Management sees limited near-term Syfovre inflection but a durable growth product plus an Empaveli-anchored nephrology franchise. It expects the deal accretive to non-GAAP EPS in 2027 and to materially raise the EPS outlook, converting a roughly flat consensus trajectory (through 2030) into a growing one onto which pipeline readouts arrive.
Funding: $3.6B cash + $2B borrowings; close expected Q2 2026.
Nephrology franchise build-out (felzartamab / Empaveli)
Biogen is assembling a nephrology franchise via Empaveli and felzartamab (CD38-targeting). It acquired China rights to felzartamab from TJ Bio (~$100M upfront plus back-end milestones), securing worldwide rights and a China entry (world's #2 pharma market). Management sized AMR at ~11,000 patients with a $2B-$3B TAM at Otsuka's ~$350K/yr IgAN price, plus 5,000-6,000 MDI/MVI patients; a Phase II showed 80% AMR resolution and IgAN durability 18 months after 9 infusions.
First felzartamab (AMR) readout expected 2027.
SMA franchise: high-dose SPINRAZA launch and Salanersen
High-dose SPINRAZA is approved in the U.S., Japan (first) and Europe, with ~20% of patients already converting in both the U.S. (hundreds of start forms) and Germany, including switches from competitors and add-ons to Zolgensma. Base SPINRAZA declined slightly on shipment timing (lumpy ex-U.S., ~9,000 of 15,000 patients) and a prior-year Europe VAT one-off📎.
Salanersen (once-yearly intrathecal) dosed its first patient in the pivotal STELLA-1/STELLAR-1 study in treatment-naive presymptomatic infants and showed durable >1-year benefit in gene-therapy-pretreated children.
LEQEMBI: persistence, biomarkers and subcutaneous roadmap
LEQEMBI market revenue rose 74% YoY to $168M with sequential growth in the U.S., Japan and China and #1 total-patient-share in all three. Real-world data showed ~80% persistence at 18 months and ~70% at 2 years. Blood-based biomarker adoption is rising, aided by new CMS reimbursement for confirmatory use and an Eisai/Biogen PCP pilot.
A subcutaneous initiation PDUFA is set for May 24, 2026 (subcu maintenance already approved), positioning easier initiation and interchangeability relevant to the presymptomatic HEAD345 population (readout 2028).
Late-stage pipeline read-out cadence
Priya emphasized a multi-year registrational data flow starting 2026 and extending through the decade: BIIB080 (tau ASO) CELIA proof-of-concept midyear 2026; Litifilimab two SLE Phase III readouts in 2026 and a CLE Phase III in early 2027 (breakthrough designation in CLE, plus positive Phase II AMITA/SLE and a second positive Phase II in CLE); felzartamab AMR Phase III in 2027; and Zorevunersen Dravet Phase III.
Management stressed disciplined pre-set go/no-go criteria, especially for the 'pioneering' BIIB080 study.
Financials and capital position
Total revenue was $2.5B (+2% YoY) with GAAP EPS $2.15 (+31%) and non-GAAP EPS $3.57 (+18%). Non-GAAP core operating expenses were ~$1.1B, comprising non-GAAP R&D of $480M (up on Phase III felzartamab and litifilimab) and non-GAAP SG&A of $600M (up on lupus/nephrology prelaunch and VUMERITY/ZURZUVAE DTC).
GAAP/non-GAAP tax rates were 15.4%/15.3%. Q1 acquired IPR&D was ~$34M (~$0.20 EPS, Alceon/Alloy) versus $165M (~$0.95 EPS, Zorevunersen) a year ago. FCF was $594M; the company exited with $4.7B cash and $1.5B net debt.